Table 3.
Participant scores for individual assays and overall laboratory performance
| Panels | Scores (%) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza A and B viruses | 882 | 1001 | 1003 | 941 | 881 | 884 | 1001 | 693 | 881 | 882 | 751 | 1005 | 881 | 882 | 632 | 756 | 631 |
| Parainfluenza viruses 1 and 3 | 1002 | 691 | 753 | 561 | 751 | 634 | 751 | nt | 631 | 882 | nt | 565 | 501 | 632 | 562 | 506 | 501 |
| Respiratory syncytial virus | 1002 | 1001 | 1003 | 1001 | 1001 | 752 | 751 | 1003 | 1002 | 502 | nt | 635 | 1001 | 502 | 752 | 506 | 251 |
| Human metapneumovirus | 1004 | 1001 | 1003 | 1001 | 1001 | 1004 | 751 | 1003 | 1004 | 1002 | 504 | nt | 1001 | 1002 | 1002 | nt | nt |
| Human rhinovirus | nt | 911 | 823 | 1001 | 731 | 1002 | 731 | 824 | 732 | nt | nt | nt | 451 | 642 | 752 | nt | nt |
| Adenovirus | 1001 | nt | nt | 881 | 1001 | 882 | 1001 | nt | 884 | 754 | 1002 | 885 | 881 | 502 | 632 | 506 | 381 |
| Human coronaviruses | nt | 881 | nt | 811 | 881 | 882 | 881 | nt | nt | nt | nt | nt | 811 | 752 | ns7 | nt | nt |
| Overall score (%) | 96.9 | 89.5 | 88.6 | 87.2 | 86.3 | 86.3 | 84.3 | 83.3 | 81.4 | 81.3 | 80 | 78.6 | 73.5 | 68.6 | 68.6 | 57.1 | 46.4 |
| Overall rank | 1 | 2 | 3 | 4 | 5 | 5 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 14 | 16 | 17 |
Methodology used as indicated by integers in superscripts: 1real-time PCR; 2nested PCR; 3nucleic acid sequence amplification (NASBA); 4single PCR; 5multiplex reverse line blot (PCR amplification with detection by reverse line blot); 6RV®Chip assay (manufactured by BCS Biotech SPA, Cagliari, Italy); 7only assay for 229E performed, nt = not tested, ns = not scored.